A Phase I, Randomised, Open-label, 3 Way Cross-over Study in Healthy Volunteers to Demonstrate the Bioequivalence of the Naloxegol 25 mg Commercial and Phase III Formulations and to Assess the Effect of Food Administration on the Pharmacokinetics of the Commercial Formulation.
Phase of Trial: Phase I
Latest Information Update: 10 Oct 2012
At a glance
- Drugs Naloxegol (Primary)
- Indications Constipation
- Focus Pharmacokinetics
- 01 Sep 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 26 Jun 2012 New trial record
- 01 Jun 2012 Actual initiation date (Jun 2012) added as reported by ClinicalTrials.gov.